Halozyme Therapeutics, Inc. Common Stock Earnings Dividend

Halozyme Therapeutics, Inc. Common Stock’s revenue jumped 42.23% since last year same period to $376.71Mn in the Q1 2026. On a quarterly growth basis, Halozyme Therapeutics, Inc. Common Stock has generated -16.61% fall in its revenue since last 3-months.

Halozyme Therapeutics, Inc. Common Stock’s net profit jumped 27.06% since last year same period to $150.05Mn in the Q1 2026. On a quarterly growth basis, Halozyme Therapeutics, Inc. Common Stock has generated 205.97% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc. Common Stock’s net profit margin fell -10.67% since last year same period to 39.83% in the Q1 2026. On a quarterly growth basis, Halozyme Therapeutics, Inc. Common Stock has generated 227.09% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc. Common Stock’s price-to-earnings ratio after this Q1 2026 earnings stands at 25.1.

Halozyme Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.82 - a 3.41% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.82.

Halozyme Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 10.02% since last year same period to 1.22 in the Q1 2026. This indicates that the Halozyme Therapeutics, Inc. Common Stock has generated 10.02% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc. Common Stock’s return on assets (ROA) stands at 0.22.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc. Common Stock’s return on equity (ROE) stands at 0.99.